You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
Microsoft is applying its Project Hanover AI to Jackson Laboratory's Clinical Knowledgebase to help tumor boards find appropriate therapies based on tumor mutations.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.